Titan Pharmaceuticals, Inc. (TTNP)

6.88 -0.18 (-2.55%) 收市：04:00PM EDT

Titan Pharmaceuticals, Inc.

400 Oyster Point Boulevard
Suite 505
South San Francisco, CA 94080
United States
650 244 4990
https://www.titanpharm.com

版塊: Healthcare
行業: Biotechnology
全職員工: 4

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. David Elliot Lazar	CEO & Principal Financial Officer	1.42M	無	1991
Dr. Katherine L. Beebe-DeVarney Ph.D.	President, COO & Director	462k	無	1961
Mr. Mike Fritz	National Sales Director	無	無	無
Jennifer Kiernan	Executive Assistant to CEO & Investor Communications Coordinator	無	無	無
Joe Schrei	Executive Director of Commercial Operations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

公司管治

截至 無 止，Titan Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。